|
|
Radioactive iodine for Graves-Basedow thyreotoxicosis (optimization of dosage regimen)
Čepková, Jitka ; Horáček, Jiří (advisor) ; Zamrazil, Václav (referee) ; Límanová, Zdeňka (referee)
2 Summary Introduction: Despite more than 60 years' experience with radioactive iodine 131 I (RAI) treatment of Graves' disease (GD) the most appropriate dosing regimen is still controversial. Namely, there has been a lot of discussion comparing the individualized dose to the fixed dose (activity). Objective: The main objective of our research was to analyze the outcome of RAI therapy depending on the initial status of patients and to relate the success rate of RAI therapy to the fixed activity and to the adjusted dose. Our practical objective was to suggest the arrangement of dosing regimen in clinical use on the basis of researched data. Patients and methods: Retrospectively, we analyzed 603 patients with GD (500 women and 103 men, mean age 51.5 ± 12.7 years) treated with RAI in our thyroid unit between the years 1998-2012. According to recommended practice in the Czech Republic, most patients came with at least 1-year history of the disease, in the first or next relapse. Their antithyroid medication was withdrawn 4 days before RAI administration. Initially, RAI activity corresponding to dose ca. 3.2-6.2 MBq/g (adjusted to thyroid volume and 24-hour RAI accumulation) was used. Since 2001, we administered at least 6.5 MBq/g, median 8.5 MBq/g. The treatment was considered successful if patients were...
|
guest ::
RSS feed.